Keystone Bio is a biotech company focused on targeting a unique inflammapath using advanced PharmaBiome technology. This approach aims to address inflammatory diseases by developing precise therapeutic interventions that improve patient outcomes.
Funding
$5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many inflammatory diseases lack targeted therapies, leading to broad immunosuppression and suboptimal patient outcomes. Current treatments often fail to address the root causes of inflammation, resulting in chronic conditions and significant side effects.
Solution
Keystone Bio is developing targeted therapeutics using its PharmaBiome technology to address the underlying inflammapathways driving inflammatory diseases. This approach aims to precisely modulate the microbiome to reduce inflammation and improve patient outcomes. By focusing on the interaction between the microbiome and the immune system, Keystone Bio seeks to develop more effective and safer treatments for a range of inflammatory conditions.
Target Audience
Keystone Bio's primary customers are patients suffering from inflammatory diseases and the healthcare providers who treat them.
Features
- PharmaBiome technology platform for targeted modulation of the microbiome
- Focus on inflammapathways to address root causes of inflammatory diseases
- Development of precise therapeutic interventions